JMS Co., Ltd. (JP:7702)
:7702
Want to see JP:7702 full AI Analyst Report?
Top Page
JMS Co., Ltd.
(7702)
Select Model
Select Model
Rating:46Neutral
Price Target:
¥413.00
▼(-6.56% Downside)
Action:Reiterated
Date:05/14/26
The score is weighed down primarily by weakening profitability and volatile/negative free cash flow, with rising leverage adding financial risk. Technicals also lean bearish with the stock below major moving averages and negative MACD. The main offset is a relatively attractive dividend yield, though losses (negative P/E) temper valuation confidence.
Positive Factors
Recurring consumables revenue model
JMS's core business sells single-use consumables tied to clinical procedures (dialysis, infusion, transfusion), creating predictable repeat demand. This attachment to procedure volume yields durable, recurring revenue streams and steady replenishment orders that support mid-term cash generation and customer stickiness.
Negative Factors
Deteriorating profitability
A recent net loss and consecutive revenue declines signal weakening operating leverage and demand pressure. Persistent earnings volatility undermines retained earnings and limits capacity to invest in product development or commercial expansion, challenging sustainable margin recovery over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables revenue model
JMS's core business sells single-use consumables tied to clinical procedures (dialysis, infusion, transfusion), creating predictable repeat demand. This attachment to procedure volume yields durable, recurring revenue streams and steady replenishment orders that support mid-term cash generation and customer stickiness.
Read all positive factors
JMS Co., Ltd. (7702) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥10.46B
Dividend Yield3.85%
Average Volume (3M)25.96K
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue Growth-5.60%
EPS Growth-981.24%
CountryJP
Employees5,283
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-11.35
Shares Outstanding24,733,465
10 Day Avg. Volume29,090
30 Day Avg. Volume25,963
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.16
P/FCF Ratio-11.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
JMS Co., Ltd. Business Overview & Revenue Model
Company Description
JMS Co.,Ltd. manufactures, sells, exports, and imports medical devices and pharmaceuticals in Japan and internationally. The company offers infusion and transfusion sets, infusion sets with a needleless access port, disposable needles and syringes...
How the Company Makes Money
JMS makes money primarily by selling medical devices and, importantly, recurring-use disposable consumables to hospitals, clinics, and distributors. Its revenue model is typically anchored in procedure-driven demand: when a provider performs dialy...
JMS Co., Ltd. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
58
Neutral
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 69.12B | 65.84B | 69.75B | 65.29B | 63.74B | 58.17B |
| Gross Profit | 15.84B | 15.36B | 15.93B | 14.09B | 14.60B | 14.27B |
| EBITDA | 4.20B | 4.22B | 4.79B | 4.08B | 4.38B | 4.59B |
| Net Income | -277.00M | -784.00M | 89.00M | -36.00M | 281.00M | 826.00M |
Balance Sheet | ||||||
| Total Assets | 80.33B | 83.07B | 81.43B | 84.71B | 74.41B | 71.97B |
| Cash, Cash Equivalents and Short-Term Investments | 6.20B | 7.72B | 5.51B | 10.31B | 6.33B | 6.81B |
| Total Debt | 23.36B | 28.01B | 24.55B | 26.92B | 19.75B | 18.71B |
| Total Liabilities | 40.34B | 41.27B | 40.50B | 43.96B | 35.70B | 34.87B |
| Stockholders Equity | 39.91B | 41.73B | 40.84B | 40.57B | 38.53B | 36.96B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -892.00M | -1.42B | 498.00M | -1.07B | 1.14B |
| Operating Cash Flow | 0.00 | 1.58B | 1.47B | 3.14B | 2.48B | 4.40B |
| Investing Cash Flow | 0.00 | -2.25B | -3.14B | -4.24B | -3.69B | -3.68B |
| Financing Cash Flow | 0.00 | 2.69B | -3.19B | 4.78B | 525.00M | -499.00M |
JMS Co., Ltd. Technical Analysis
Negative
442.00
Price Trends
429.43
Negative
431.98
Negative
430.81
Negative
Market Momentum
-0.39
Negative
49.69
Neutral
40.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7702, the sentiment is Negative. The current price of 442 is above the 20-day moving average (MA) of 427.25, above the 50-day MA of 429.43, and above the 200-day MA of 430.81, indicating a neutral trend. The MACD of -0.39 indicates Negative momentum. The RSI at 49.69 is Neutral, neither overbought nor oversold. The STOCH value of 40.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7702.
JMS Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ¥999.21B | 32.62 | 11.64% | 0.82% | 15.13% | 196.11% | |
71 Outperform | ¥3.55T | 26.06 | 8.98% | 1.22% | 9.24% | 16.68% | |
65 Neutral | ¥1.97T | 28.96 | 11.34% | 1.01% | 1.34% | -40.50% | |
54 Neutral | ¥280.69B | 20.79 | 4.38% | 2.03% | 2.47% | 164.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | ¥10.46B | -13.39 | ― | 3.85% | -5.60% | -981.24% |
* Healthcare Sector Average
JP:7702
JMS Co., Ltd.
428.00
17.93
4.37%
JP:4543
Terumo
2,401.00
-189.55
-7.32%
JP:7747
Asahi Intecc Co
3,766.00
1,555.76
70.39%
JP:8086
Nipro
1,721.00
488.28
39.61%
JP:7733
Olympus
1,785.50
-18.42
-1.02%
JMS Co., Ltd. Corporate Events
JMS Posts Fiscal 2026 Loss but Strengthens Balance Sheet and Liquidity
May 12, 2026
JMS Co., Ltd. reported a decline in net sales to ¥65.8 billion for the fiscal year ended March 2026, down 5.6% from the prior year, with operating profit halving to ¥381 million and ordinary profit dropping 30.8%. The company swung to a ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.